Navigation Links
Rigel Earns Milestone Payments From AstraZeneca
Date:9/29/2010

SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor.  The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.  The second milestone marks the completion of the transfer of the fostamatinib long-term open label extension study from Rigel to AstraZeneca.

"We are proud of our team's ability to successfully and smoothly transition both aspects of the fostamatinib program to AstraZeneca in just six months time, and are pleased to know that fostamatinib will be the focus of one of the largest phase 3 studies in RA patients conducted to date," said James M. Gower, chairman and chief executive officer of Rigel.

In February 2010, Rigel granted AstraZeneca exclusive rights to the future development and commercialization of fostamatinib. AstraZeneca announced that the initial primary focus of their phase 3 clinical development program for fostamatinib, called OSKIRA (Oral Syk Inhibition in Rheumatoid Arthritis), would be in patients with RA, with an inadequate response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate.

In today's announcement, AstraZeneca outlined the scope of their global clinical trial program, which will include three pivotal phase 3 studies assessing the efficacy and tolerability of fostamatinib. Results are expected to allow for the filing of new drug applications with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) in 2013.

Fostamatinib and RA

RA is a systemic autoimm
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rigel to Host Update Conference Call
2. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
3. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
4. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
5. Rigel to Participate at the RBC Capital Markets Healthcare Conference
6. Rigel to Present at Citis Biotech Day
7. Rigel Announces First Quarter 2009 Financial Results
8. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
9. Aerospace engineer earns Oak Ridge Associated Universities Ralph Powe Junior Faculty Award
10. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
11. Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that company CEO, David ... , The presentation took place on Tuesday, June 16 and provided an ... of APX3330 for the treatment of pancreatic cancer. A copy of the company ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... Francisco, CA (PRWEB) , ... June 30, 2015 ... ... FMT Patients , Study will provide new insights on mechanics of fecal microbiota ... a new partnership to study the microbiome of patients undergoing fecal microbiota transplantation ...
(Date:6/30/2015)...  The University of California, San Diego,s Center ... San Diego Extension announced their third annual workshop ... – 14, 2015, at UC San Diego (see ... intense exposure to best practices and the latest ... biologists, process engineers and business executives planning next ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2
... ARCA biopharma, Inc.,announced today that the U.S. ... New Drug Application (NDA) for the company,s ... unique,beta-blocker and mild vasodilator developed for the ... the FDA, bucindolol could become the first,genetically ...
... HOUSTON, Sept. 22, 2008 -- Chemists at Rice University ... nanorods -- tiny, wand-like nanoparticles that are being studied ... as diagnosing disease and improving electronic viewscreens. , "The ... synthetic methods is only about 20 percent," said lead ...
... SAN DIEGO, Sept. 22 Neurocrine Biosciences,Inc. (Nasdaq: ... and Chief,Executive Officer of Neurocrine Biosciences will be presenting ... Hyatt in New York., The live presentation takes ... (ET) /7:00 a.m. Pacific Time (PT). The presentation will,be ...
Cached Biology Technology:FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 2FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 3Purifying nanorods: Big success with tiny cleanup 2Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference 2
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
(Date:6/9/2015)... , June 9, 2015   MedNet Solutions ... the entire spectrum of clinical research, will be providing ... technology platform at the 2015 Drug Information Association (DIA) ... on June 15-17.  These presentations will include previews of ... out in the upcoming iMedNet 2015 Feature ...
(Date:6/8/2015)...  The Secure Identity & Biometrics Association ... Troy Potter of L-3 National Security Solutions ... non-profit association that was established in February 2014 ... of solutions that protect and secure identity across ... Photo - ...
Breaking Biology News(10 mins):Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... the forthcoming issue of the Journal of Integrated ... that the western bean cutworm (WBC), Striacosta albicosta ... "caused by genetically engineered corn." The Greenpeace Germany report, ... offers a "surprisingly simplistic conclusion" regarding the spread of ...
... may sound delicious, but local fishermen would rather keep ... are protected by fishing limits yet frequently surface in ... of this unintended butterfish "bycatch" can get a fishery ... the squid allocation is caught. The University of ...
... new strategies for tackling the challenges of preventing and ... and Huntington,s diseases, amyotrophic lateral sclerosis (ALS), cancer, cystic ... job properly within the cell, a protein first must ... trouble can result. More than 300 diseases have at ...
Cached Biology News:Scientists refute Greenpeace claim that genetically modified corn caused new insect pest 2University scientists aiding fishermen in butterfish conundrum 2University scientists aiding fishermen in butterfish conundrum 3Tiny worm points to big promise 2Tiny worm points to big promise 3
...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
... CELSR3 CELSR3 is an Orphan-U GPCR ... gene is expressed during development at sites of ... in brain, spinal cord, dorsal root ganglion, and ... blood, brain, colon, heart/melanocyte/uterus, lung, nerve, and placenta ...
...
Biology Products: